Halozyme Therapeutics (HALO) Short Interest Ratio & Short Volume

Short interest is the volume of Halozyme Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, investors have sold 6,970,000 shares of HALO short. 5.33% of Halozyme Therapeutics' shares are currently sold short. Learn More on Halozyme Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HALO shares currently have a short interest ratio of 8.0. Learn More on Halozyme Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Halozyme Therapeutics: Walleye Trading LLC, Walleye Capital LLC, Wolverine Trading LLC, Wolverine Asset Management LLC, Group One Trading L.P., Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.33% of Halozyme Therapeutics' floating shares are currently sold short.

Halozyme Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 6,970,000 shares, an increase of 5.9% from the previous total of 6,580,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Halozyme Therapeutics currently has issued a total of 132,100,000 shares. Some of Halozyme Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Halozyme Therapeutics currently has a public float of 130,790,000 shares.

5.33% of Halozyme Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Halozyme Therapeutics: Exelixis, Inc. (3.21%), Repligen Co. (11.54%), Neurocrine Biosciences, Inc. (2.32%), Immunovant, Inc. (11.64%), Abcam plc (2.43%), CRISPR Therapeutics AG (20.61%), Vaxcyte, Inc. (7.64%), Ginkgo Bioworks Holdings, Inc. (17.15%), Krystal Biotech, Inc. (7.34%), ImmunityBio, Inc. (5.34%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling HALO is an investing strategy that aims to generate trading profit from Halozyme Therapeutics as its price is falling. HALO shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Halozyme Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HALO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HALO, twice per month. The most recent reporting period available is November, 15 2023.